|
Aug 8
|
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 8
|
Xeris Biopharma: Q2 Earnings Snapshot
|
|
Aug 8
|
Xeris Biopharma Reports Second Quarter 2024 Financial Results
|
|
Jul 25
|
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
|
|
Jul 24
|
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
|
|
May 30
|
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
|
|
May 30
|
Xeris to Participate in the Jefferies Global Healthcare Conference
|
|
May 10
|
Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges
|
|
May 10
|
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Xeris Biopharma Holdings First Quarter 2024 Earnings: Misses Expectations
|
|
May 10
|
Q1 2024 Xeris Biopharma Holdings Inc Earnings Call
|
|
May 9
|
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 9
|
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
|
|
May 6
|
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
|
|
May 2
|
Pleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings Stock
|
|
May 2
|
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 17
|
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
|
|
Apr 5
|
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
|
|
Apr 3
|
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
Apr 2
|
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|